April 22, 2025
Ensem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636
January 6, 2025
Ensem Therapeutics Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
December 10, 2024
Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Oral CDK2 Inhibitor at San Antonio Breast Cancer Symposium
December 10, 2024
Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader at San Antonio Breast Cancer Symposium
June 12, 2024
Ensem Therapeutics Announces Achievement of Milestone Following Entry of Small Molecule CDK2 Inhibitor into Clinical Trials for Solid Tumors
January 3, 2024
ENSEM Expands its Leadership Team with the Appointment of Jeff Kutok, M.D., Ph.D. as Chief Scientific Officer
November 21, 2023
BeiGene stakes out space in hot cancer niche, offering up $1.3B in biobucks for preclinical prospect
November 21, 2023
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
June 5, 2023
ENSEM Announces the Promotion of Shengfang Jin, PhD to President & Chief Executive Officer
April 7, 2022
With an eye to ‘non-obvious binding sites,’ CBC Group launches precision medicine play with $67M and ex-Editas exec at the helm
April 6, 2022
Ensem Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets
Subscribe
